When was ARTHEx founded?

ARTHEx was founded in 2018 and raised its 1st funding round 1 year after it was founded.

Where is ARTHEx located?

ARTHEx is headquartered in Valencia, Spain.

How many employees does ARTHEx have?

As of Aug 31, 2026, the latest employee count at ARTHEx is 32.

Is ARTHEx a funded company?

ARTHEx is a funded company, having raised a total of $93.6M across 9 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Dec 2019.

When was the latest funding round of ARTHEx?

ARTHEx's latest funding was a $***** Series B round on Sep 17, 2025, with participation from 8 investors.

Where does ARTHEx rank among its competitors?

ARTHEx ranks 64th amongst 574 active competitors, of which 209 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was ARTHEx, which secured $40.6M in Sep, 2025.

Who are the top competitors of ARTHEx?

ARTHEx's top competitors include Alnylam, Spark Therapeutics and Forge Biologics. Among them, ARTHEx secured the most recent funding round in September, 2025.

ARTHEx - 2026 Company Profile, Team, Funding & Competitors

ARTHEx is a series B company based in Valencia (Spain), founded in 2018 by Ruben Artero and Beatriz Llamusi. It operates as a Developer of oligonucleotide therapies for neuromuscular diseases. ARTHEx has raised $93.6M in funding from investors like Invivo Ventures, Europa and Bpifrance. The company has 574 active competitors, including 209 funded and 137 that have exited. Its top competitors include companies like Alnylam, Spark Therapeutics and Forge Biologics.

Company Details

Developer of oligonucleotide therapies for neuromuscular diseases. The company offers products that are involved in neuromuscular diseases, focusing on Myotonic Dystrophy. The company's lead candidate inhibits miRNAs from repressing MBNL1/2, to compensate for MBNL loss of function.

Website: www.arthexbiotech.com/
Social

Key Metrics

Founded Year

2018

Location

Valencia, Spain

Stage

Series B

Total Funding

$93.6M in 9 rounds

Latest Funding Round

Series B, Sep 17, 2025, $*****

Investors

Invivo Ventures & 12 more

Ranked

64^th among 574 active competitors

Employee Count

32 as on Aug 31, 2026

Similar Companies

Alnylam & 716 more

View ARTHEx's full profile

ARTHEx has raised a total funding of $93.6M over 9 rounds. Its first funding round was on Dec 2019. Its latest funding round was a Series B round on Sep 17, 2025 for $*****. 8 investors participated in its latest round. ARTHEx has 13 institutional investors.

Here is the list of recent funding rounds of ARTHEx:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 17, 2025	6088872	Series B	2839534	2590841	3937147	2986330
May 04, 2023	8731026	Series B	4848673	8045465	5503146	CDTI & 5 more
Mar 21, 2023	2773262	Grant (prize money)	9221414	5184614	4446462	European Investment Bank

Access funding benchmarks and valuations. Sign up today!

View details of ARTHEx's funding rounds and investors

The founders of ARTHEx are Ruben Artero and Beatriz Llamusi.

Here are the details of ARTHEx's key team members:

Ruben Artero: Co-Founder of ARTHEx.
Beatriz Llamusi: Co-Founder & CEO of ARTHEx.
Contact Info: 1 email address

View details of ARTHEx's Founder profiles and Board Members

ARTHEx's employee count trend

ARTHEx has 32 employees as of Aug 26. Here is ARTHEx's employee count trend over the years:

Uncover ARTHEx's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of ARTHEx include Alnylam, Spark Therapeutics and Forge Biologics. Here is the list of Top 10 competitors of ARTHEx, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	79/100
2nd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
3rd	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	Aisling Capital, RA Capital Management & 7 others	70/100
4th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	70/100
5th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
6th	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	F-Prime Capital, Adage Capital Management ... & 10 others	69/100
7th	Generation Bio 2016, Cambridge (United States), Acquired	Developer of gene therapies for rare liver and eye diseases	$236M	T. Rowe Price, Fidelity Investments & 9 others	69/100
8th	ElevateBio 2018, Cambridge (United States), Series D	Provider of transnational research for portfolio of cell and gene therapy	$1.25B	Matrix Capital Management, EDBI & 16 others	68/100
9th	Krystal Biotech 2015, Pittsburgh (United States), Public	Developer of genetic medicines to treat rare diseases	$11.3M	Frazier Life Sciences, Danforth Advisors & 2 others	67/100
10th	Sirnaomics 2007, Gaithersburg (United States), Public	Developer of RNA based therapeutics for the treatment of cancer and fibrosis disease	$267M	Rotating Boulder Fund, Walvax & 16 others	67/100
64th	ARTHEx 2018, Valencia (Spain), Series B	Developer of oligonucleotide therapies for neuromuscular diseases	$93.6M	Hadean Ventures, Columbus Venture Partners ... & 11 others	58/100